Damien Goldberg, MD
Ophthalmology · Torrance, CANPI 1891833695
Payments from drug & device makers
Across 2,619 payments — averaging $1566.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$886K
- AbbVie$864K
- Johnson & Johnson Surgical Vision, Inc.$757K
- Ocular Therapeutix, Inc.$592K
- Glaukos Corporation$433K
- Bausch Health US, LLC$275K
- plus $295K from 20 others
Across 92 payments — averaging $2108.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- NEW World Medical,inc.$111K
- Bausch Health US, LLC$80K
- Glaukos Corporation$2K
- Ocular Therapeutix, Inc.$1K
What the payments were for
- Consulting fees$76,06371%
- Speaking & faculty fees$18,68217%
- Travel & lodging$1,0201%
- Food & beverage$8,9688%
- Education$50%
- Entertainment$270%
- Other$2,1782%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 1,729 | $885,695 |
| AbbVie(2 entities) | 309 | $863,742 |
| Johnson & Johnson Surgical Vision, Inc. | 50 | $756,930 |
| Ocular Therapeutix, Inc. | 33 | $592,180 |
| Glaukos Corporation | 182 | $432,867 |
| Bausch Health US, LLC | 49 | $275,108 |
| Kala Pharmaceuticals, Inc. | 15 | $70,286 |
| Carl Zeiss Meditec Production LLC | 4 | $64,820 |
| Bausch & Lomb Americas Inc. | 33 | $54,768 |
| NEW World Medical,inc. | 36 | $37,103 |
| Rxsight Inc | 16 | $30,254 |
| Oyster Point Pharma, Inc. | 26 | $18,992 |
| Alcon | 66 | $14,378 |
| Lensar, Inc. | 2 | $2,000 |
| Novartis | 24 | $428 |
| Carl Zeiss Meditec, Inc. | 4 | $339 |
| Carl Zeiss Meditec USA, Inc. | 4 | $334 |
| Tarsus Pharmaceuticals, Inc. | 10 | $296 |
| Sun Pharmaceutical Industries Inc. | 10 | $247 |
| Shire North American Group Inc | 7 | $240 |
| Staar Surgical Company | 3 | $204 |
| Dompe US, Inc. | 2 | $55 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $38 |
| Mallinckrodt Enterprises LLC | 1 | $25 |
| Amgen | 1 | $22 |
| Thea Pharma Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$16,752
- Kahook Dual Blade$16,752
- XEN$10,288
- Streamline Surgical System$9,921
- RESTASIS$5,329
- AcrySof IQ PanOptix$5,000
- AcrySof IQ VIVITY IOL$4,125
- DURYSTA$3,300
- AcrySof IQ PanOptix UV IOL$2,637
- AcrySof IQ VIVITY$2,500
- Clearpath$2,481
- Streamline$2,481
- CVISC50$2,400
- iDose$2,178
- LENSAR LASER SYSTEM$2,000
- EYSUVIS$1,300
- iStent inject Trabecular Micro-Bypass Stent System$1,000
- Unity$619
- iStent Trabecular Micro-Bypass Stent System$500
- VERACITY SURGICAL$439
How this compares
$4,101,372 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 444 | $361,682 |
| XiidraLifitegrast | 199 | $203,291 |
| Cyclosporine | 250 | $92,776 |
| LumiganBimatoprost | 88 | $44,378 |
| XdemvyLotilaner | 19 | $36,412 |
| MieboPerfluorohexyloctane/Pf | 32 | $25,233 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 86 | $14,799 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 70 | $14,112 |
| Travoprost | 57 | $10,523 |
| Prednisolone Acetate | 285 | $9,714 |
| CequaCyclosporine | 13 | $9,268 |
| RhopressaNetarsudil Mesylate | 17 | $9,004 |
| Latanoprost | 778 | $8,426 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $8,236 |
| VyzultaLatanoprostene Bunod | 18 | $7,352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $863,742 | $419,210563 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $54,768 | $235,876249 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $296 | $36,41219 claims |
| AlconSimbrinza | $14,378 | $14,11270 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $247 | $9,26813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Torrance
- Mehran TabanTorrance$893K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.